Alzprotect
is a France-based biopharmaceutical company that develops and commercializes therapeutics for the treatment of neurodegenerative diseases... Read moreAlzprotect
is a France-based biopharmaceutical company that develops and commercializes therapeutics for the treatment of neurodegenerative diseases... Read more
News
Sep 18, 2024
FinanzNachrichten
Alzprotect: Alzprotect Announces Supportive Results from Open-Label Extension of Phase 2a Study for Progressive Supranuclear Palsy (PSP)
Mar 13, 2024
FinanzNachrichten
Alzprotect: Positive Feedback From the EMA and FDA on Alzprotect's Phase 2b/3 Development Strategy for PSP
Jun 01, 2022
FirstWord Pharma
Alzprotect: Alzprotect Awarded a Grant from The Michael J. Fox Foundation to Advance Small Molecule Parkinson's Disease Program
Jun 22, 2021
EIN Presswire
Press Release: Alzprotect : Alzprotect strengthens its Board of Directors with the arrival of Dr. John Tchelingerian
Apr 08, 2021
EIN Presswire
Press Release: Alzprotect : Alzprotect Establishes U.S. Subsidiary in Boston, in the Heart of the Biotech Cluster
Nov 23, 2020
MarketScreener
Alzprotect: Alzprotect : Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind
Sep 14, 2020
MarketScreener
Alzprotect: Alzprotect : Forges Ahead with First Patients Enrolled in Phase 2a Study in Progressive Supranuclear Palsy (PSP)
Mar 25, 2019
Contract Pharma
Alzprotect: AlzProtect & PAREXEL Biotech Enter Collaboration
Feb 20, 2019
BioPortfolio
Alzprotect: AlzProtect on Track for a Phase 2 Entry in 2019 for its Drug Candidate AZP2006
May 03, 2017
BioSpace
Alzprotect: AlzProtect: The American FDA Has Granted AZP2006 the Orphan Drug Designation for the Treatment of Progressive Supranuclear Palsy (PSP)
